1·Considering the powerful effects of lifestyle interventions in other trials, this design feature may have reduced the magnitude of the potential benefit from nateglinide.
考虑到其它试验中生活方式干预的强大效应，本研究的设计可能已经减少了那格列奈潜在利益的幅度。
2·Finally, owing to its rapid-action profile, nateglinide has a relatively low risk of causing hypoglycemia.
最后，由于起效快，那格列奈造成低血糖风险相对较低。
3·To optimize the formula of the double-layer tablet of nateglinide rapid-release layer and metformin hydrochloride sustained-release layer.
优选由那格列奈速释层与盐酸二甲双胍缓释层组成的双层片处方。
4·OBJECTIVE To establish the dissolution method for nateglinide tablets.
目的：建立那格列奈片的体外溶出度的测定方法。
5·Nateglinide is a novel non-sulfonylurea antidiabetic agent by stimulating insulin secretion. Its action occurs rapidly and sustains shortly.
那格列奈是一种新型的非磺酰脲类促胰岛素分泌的降糖新药，其起效快且作用时间较短。